Wegovy

Research shows GLP-1 agonists like Wegovy may reduce Alzheimer’s risk by up to 54% through anti-inflammatory pathways—here’s what the clinical evidence

Wegovy (semaglutide) shows emerging evidence of reducing alcohol intake in some patients through GLP-1 receptor pathways affecting reward signaling.

Wegovy doesn’t cause gambling addiction through direct neurochemical action, but GLP-1 receptor changes can unmask compulsive behaviors in predisposed

Wegovy doesn’t treat nicotine dependence — it targets GLP-1 receptors for weight loss, not addiction pathways. Here’s what the research shows.

Wegovy may trigger compulsive shopping in some patients through dopamine pathway changes. We explain the mechanism, warning signs, and what to do if it

Wegovy doesn’t directly treat social anxiety, but weight loss can improve confidence. Here’s what clinical evidence shows about GLP-1 medications and

Wegovy shows limited efficacy for lipedema fat — GLP-1 agonists target metabolic adipose tissue, not lipedema’s pathological lymphatic deposits.

If you have Cigna insurance and are wondering whether your plan covers Wegovy, there are two names worth knowing: Cigna and Express Scripts. Cigna…

Aetna is one of the largest health insurers in the United States, but asking whether Aetna covers Wegovy is a bit like asking whether…